Literature DB >> 10992459

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

P C Melby1, G B Ogden, H A Flores, W Zhao, C Geldmacher, N M Biediger, S K Ahuja, J Uranga, M Melendez.   

Abstract

Visceral leishmaniasis caused by the intracellular parasite Leishmania donovani is a significant public health problem in many regions of the world. Because of its large genome and complex biology, developing a vaccine for this pathogen has proved to be a challenging task and, to date, protective recombinant vaccine candidates have not been identified. To tackle this difficult problem, we adopted a reductionist approach with the intention of identifying cDNA sequences in an L. donovani amastigote cDNA library that collectively or singly conferred protection against parasite challenge in a murine model of visceral leishmaniasis. We immunized BALB/c mice with plasmid DNA isolated and pooled from 15 cDNA sublibraries ( approximately 2,000 cDNAs/sublibrary). Following systemic challenge with L. donovani, mice immunized with 6 of these 15 sublibraries showed a significantly reduced (35- to 1,000-fold) hepatic parasite burden. Because of the complexity and magnitude of the sequential fractionation-immunization-challenge approach, we restricted our attention to the two sublibraries that conferred the greatest in vivo protection. From one of these two sublibraries, we identified several groups of cDNAs that afforded protection, including a set of nine novel cDNAs and, surprisingly, a group of five cDNAs that encoded L. donovani histone proteins. At each fractionation step, the cDNA sublibraries or the smaller DNA fractions that afforded in vivo protection against the parasite also induced in vitro parasite-specific T helper 1 immune responses. Our studies demonstrate that immunization with sequential fractions of a cDNA library is a powerful strategy for identifying anti-infective vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992459      PMCID: PMC101511          DOI: 10.1128/IAI.68.10.5595-5602.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

Review 1.  Modulation of host immune responses by protozoal DNA.

Authors:  W C Brown; C E Suarez; L K Shoda; D M Estes
Journal:  Vet Immunol Immunopathol       Date:  1999-12-15       Impact factor: 2.046

Review 2.  DNA immunization targeting the skin: molecular control of adaptive immunity.

Authors:  T Tüting; W J Storkus; L D Falo
Journal:  J Invest Dermatol       Date:  1998-08       Impact factor: 8.551

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.

Authors:  M Kozak
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

5.  Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity.

Authors:  H W Murray; H Masur; J S Keithly
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

6.  New perspectives on a subclinical form of visceral leishmaniasis.

Authors:  R Badaro; T C Jones; E M Carvalho; D Sampaio; S G Reed; A Barral; R Teixeira; W D Johnson
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

7.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

8.  Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.

Authors:  C L Jaffe; N Rachamim; R Sarfstein
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

9.  Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.

Authors:  J J Stern; M J Oca; B Y Rubin; S L Anderson; H W Murray
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

10.  Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.

Authors:  E M Carvalho; O Bacellar; A Barral; R Badaro; W D Johnson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more
  21 in total

1.  Long-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii.

Authors:  Alberto Fachado; Alexandro Rodriguez; Judith Molina; Jaline C Silvério; Ana P M P Marino; Luzia M O Pinto; Sergio O Angel; Juan F Infante; Yara Traub-Cseko; Regina R Amendoeira; Joseli Lannes-Vieira
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

2.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 4.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

5.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.

Authors:  Salvador Iborra; Manuel Soto; Javier Carrión; Ana Nieto; Edgar Fernández; Carlos Alonso; Jose M Requena
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

Authors:  A Rainczuk; T Scorza; P M Smooker; T W Spithill
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors:  Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.